At Cloud Pharmacy, your safety and wellbeing always come first. We are pleased to announce an important update to our Wegovy (Semaglutide) treatment policy that supports patients continuing their long-term weight management journey.
A New Chapter in Wegovy Treatment
Wegovy is licensed for both weight loss and weight maintenance as part of a reduced-calorie diet and increased physical activity. It has been proven to help patients with obesity achieve significant weight reduction and improve their overall health.
What Has Changed?
Until recently, Wegovy prescriptions were limited to a maximum of two years based on earlier national guidance from NICE (National Institute for Health and Care Excellence) published in September 2023.
At that time, the STEP 5 clinical trial provided the longest available data, showing semaglutide was safe and effective for up to two years of continuous use.
More up-to-date evidence from the SELECT trial now extends that understanding. Participants used semaglutide for an average of almost 40 months (over three years) with no increase in serious side effects compared to placebo, confirming its safety and sustained effectiveness beyond two years.
Importantly, research from follow-up studies such as the STEP 1 trial extension has also shown that patients who stop semaglutide completely can regain up to two-thirds of their prior weight loss within one year of discontinuation.
This combination of evidence, demonstrating both the safety of long-term use and the risk of significant weight regain after stopping, has guided our decision to remove the two-year treatment cap at Cloud Pharmacy.
You can now continue Wegovy for as long as it remains clinically appropriate, with ongoing medical review and support from our prescribing team.
Why This Matters
Wegovy treatment occurs in two stages:
- The weight-loss phase, where you achieve your target results.
- The maintenance phase, where the focus is on maintaining weight loss and long-term health
This change is especially important for those entering the maintenance phase.
Research shows that people who stop semaglutide completely can regain up to two-thirds of their previous weight loss within one year after discontinuation.
Continuing Wegovy during maintenance helps to preserve your progress, support metabolic health, and reduce the risk of weight regain.
Your Maintenance Plan on Wegovy
The licensed maintenance dose of Wegovy is 2.4 mg once weekly.
This is the standard dose shown to deliver the best long-term outcomes for weight control and cardiometabolic health.
Your prescriber will personalise your plan based on your response and tolerability.
Common approaches include:
- Continuing at the same dose if it is effective
- Reducing the dose to maintain stability
- Tapering down under supervision
- Discontinuing in a planned, supported way
Stopping suddenly is not recommended, as this can lead to rapid weight regain.
Your prescriber will always help you decide the safest and most suitable approach.
Safe and Individualised Care
What remains consistent is our commitment to ensuring your care is safe, evidence-based, and fully supported.
At Cloud Pharmacy, Wegovy is prescribed responsibly and within its licensed use, guided by the latest clinical research. Our team of experienced prescribers will work closely with you to monitor your progress, assess how your body responds, and make adjustments where needed to keep your treatment safe and effective.
We understand that maintaining results takes time and consistency. That is why our clinical team provides ongoing guidance and personalised support to help you stay on track, sustain your progress, and feel confident in your long-term plan for health and wellbeing.
Continuing Your Journey
Weight management is a lifelong process and Wegovy can play an important role in helping you achieve lasting success. Whether you are still working toward your weight loss goals or are maintaining your results, our team is here to provide continuous support and clinical guidance.
Our aim is to ensure your treatment remains safe, effective, and sustainable so that you can maintain your progress and enjoy the long-term health benefits that come with continued Wegovy care.
References
1. Novo Nordisk Ltd. Wegovy 2.4 mg solution for injection in pre-filled pen — Summary of Product Characteristics. Medicines.org.uk; 2025. Available from: https://www.medicines.org.uk/emc/product/13799/smpc
2. National Institute for Health and Care Excellence (NICE). Semaglutide for managing overweight and obesity (TA875). NICE; 2023. Available from: https://www.nice.org.uk/guidance/ta875
3. Wadden TA, Garvey WT, Rubino DM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(22):2051–2062. Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
4. Wilding JPH, Batterham RL, Calanna S, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(9):1553–1562. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC9542252
